Evidence map›Paper›PMID 38907004›Full record

ArticleEuropean journal of human genetics : EJHG2024

Limitations in next-generation sequencing-based genotyping of breast cancer polygenic risk score loci.

Alexandra Baumann, Christian Ruckert, Christoph Meier, Tim Hutschenreiter, Robert Remy, Benedikt Schnur, Marvin Döbel, Rudel Christian Nkouamedjo Fankep, Dariush Skowronek, Oliver Kutz and 14 more

Abstract read
In one paragraph

Article in European journal of human genetics : EJHG, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. PRS-BCJournal of medical genetics · 2026
    Article
  2. Article
  3. Case Report: A combination ofFrontiers in oncology · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Alexandra BaumannInstitute for Clinical Genetics, University Hospital Carl Gustav Carus at TUD Dresden University of Technology and Faculty of Medicine of TUD Dresden University of Technology, Dresden, Germany.
Christian RuckertDepartment of Medical Genetics, University Hospital Münster, Münster, Germany.
Christoph MeierInstitute of Human Genetics, University of Regensburg, Regensburg, Germany.
Tim HutschenreiterInstitute for Clinical Genetics, University Hospital Carl Gustav Carus at TUD Dresden University of Technology and Faculty of Medicine of TUD Dresden University of Technology, Dresden, Germany.
Robert RemyCenter for Familial Breast and Ovarian Cancer, Center for Integrated Oncology (CIO), Medical Faculty, University of Cologne and University Hospital Cologne, Cologne, Germany.
Benedikt SchnurDepartment of Human Genetics, Hannover Medical School (MHH), Hannover, Germany.ORCID 0000-0002-1977-7878
Marvin DöbelInstitute of Medical Genetics and Applied Genomics, University Hospital Tübingen, Tübingen, Germany.ORCID 0000-0002-8024-2178
Rudel Christian Nkouamedjo FankepCenter for Familial Breast and Ovarian Cancer, Center for Integrated Oncology (CIO), Medical Faculty, University of Cologne and University Hospital Cologne, Cologne, Germany.
Dariush SkowronekDepartment of Human Genetics, University Medicine Greifswald and Interfaculty Institute of Genetics and Functional Genomics, University of Greifswald, Greifswald, Germany.
Oliver KutzInstitute for Clinical Genetics, University Hospital Carl Gustav Carus at TUD Dresden University of Technology and Faculty of Medicine of TUD Dresden University of Technology, Dresden, Germany.
Norbert ArnoldDepartment of Gynecology and Obstetrics, Institute of Clinical Chemistry Institute of Clinical Molecular Biology, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany.
Anna-Lena KatzkeDepartment of Human Genetics, Hannover Medical School (MHH), Hannover, Germany.
Michael ForsterDepartment of Gynecology and Obstetrics, Institute of Clinical Chemistry Institute of Clinical Molecular Biology, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany.ORCID 0000-0001-9927-5124
Anna-Lena KobielaCenter for Familial Breast and Ovarian Cancer, Center for Integrated Oncology (CIO), Medical Faculty, University of Cologne and University Hospital Cologne, Cologne, Germany.ORCID 0009-0000-6391-1280
Katharina ThiedigDivision of Gynaecology and Obstetrics, Klinikum rechts der Isar der Technischen Universität München, München, Germany.
Andreas ZimmerInstitute for Human Genetics, Medical Center University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.ORCID 0000-0002-5595-9388
Julia RitterDepartment of Human Genetics, Labor Berlin - Charité Vivantes GmbH, Berlin, Germany.
Bernhard H F WeberInstitute of Human Genetics, University of Regensburg, Regensburg, Germany.ORCID 0000-0002-8808-7723
Ellen HonischDepartment of Gynaecology and Obstetrics, University Hospital Düsseldorf, Heinrich-Heine University Düsseldorf, Düsseldorf, Germany.
Karl HackmannInstitute for Clinical Genetics, University Hospital Carl Gustav Carus at TUD Dresden University of Technology and Faculty of Medicine of TUD Dresden University of Technology, Dresden, Germany.ORCID 0000-0003-4181-2120
Bioinformatics Working Group of the German Consortium for Hereditary Breast & Ovarian Cancer
Gunnar SchmidtDepartment of Human Genetics, Hannover Medical School (MHH), Hannover, Germany.
Marc SturmInstitute of Medical Genetics and Applied Genomics, University Hospital Tübingen, Tübingen, Germany.ORCID 0000-0002-6552-8362
Corinna ErnstCenter for Familial Breast and Ovarian Cancer, Center for Integrated Oncology (CIO), Medical Faculty, University of Cologne and University Hospital Cologne, Cologne, Germany. corinna.ernst@uk-koeln.de.ORCID 0000-0001-7756-8815

Funding

Bundesministerium für Gesundheit (Federal Ministry of Health, Germany) genomDEDeutsche Krebshilfe (German Cancer Aid) HerediVar
6 · The paper itself

Abstract

Considering polygenic risk scores (PRSs) in individual risk prediction is increasingly implemented in genetic testing for hereditary breast cancer (BC) based on next-generation sequencing (NGS). To calculate individual BC risks, the Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm (BOADICEA) with the inclusion of the BCAC 313 or the BRIDGES 306 BC PRS is commonly used. The PRS calculation depends on accurately reproducing the variant allele frequencies (AFs) and, consequently, the distribution of PRS values anticipated by the algorithm. Here, the 324 loci of the BCAC 313 and the BRIDGES 306 BC PRS were examined in population-specific database gnomAD and in real-world data sets of five centers of the German Consortium for Hereditary Breast and Ovarian Cancer (GC-HBOC), to determine whether these expected AFs can be reproduced by NGS-based genotyping. Four PRS loci were non-existent in gnomAD v3.1.2 non-Finnish Europeans, further 24 loci showed noticeably deviating AFs. In real-world data, between 11 and 23 loci were reported with noticeably deviating AFs, and were shown to have effects on final risk prediction. Deviations depended on the sequencing approach, variant caller and calling mode (forced versus unforced) employed. Therefore, this study demonstrates the necessity to apply quality assurance not only in terms of sequencing coverage but also observed AFs in a sufficiently large cohort, when implementing PRSs in a routine diagnostic setting. Furthermore, future PRS design should be guided by the technical reproducibility of expected AFs across commonly used genotyping methods, especially NGS, in addition to the observed effect sizes.

Indexed as

Breast NeoplasmsMultifactorial InheritanceAlgorithmsFemaleGene FrequencyGenetic Predisposition to DiseaseGenetic Risk ScoreGenetic TestingGenotyping TechniquesHigh-Throughput Nucleotide SequencingHumans

Identifiers

PMID38907004
PMCPMC11291653

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.